Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 1:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lunesta Clear all
Completed Phase 4 Interventional Results available

Improving Sleep and Psychological Functioning in People With Depression and Insomnia

NCT00247624
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Depression
Interventions
Eszopiclone, Fluoxetine, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Sep 7, 2026, 1:34 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Combining Behavioral and Pharmacologic Therapy for Complex Insomnia in Veterans With PTSD

NCT03937713
View directory record Official record
Conditions
Complex Insomnia
Interventions
eszopiclone, Brief behavioral therapy for insomnia
Drug · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 7, 2026, 1:34 AM EDT
Recruiting Phase 1Phase 2 Interventional

Rescue Pharmacotherapy for OSA

NCT05293600
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Placebo, Acetazolamide, Trazodone, Atomoxetine and eszopiclone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 7, 2026, 1:34 AM EDT
Completed Phase 3 Interventional Results available

Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia

NCT00857220
View directory record Official record
Conditions
Insomnia, Attention Deficit Hyperactivity Disorder
Interventions
eszopiclone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
89
States / cities
Tucson, Arizona • Little Rock, Arkansas • Carson, California + 70 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Sep 7, 2026, 1:34 AM EDT
Completed Phase 4 Interventional Results available

Eszopiclone for the Treatment of Posttraumatic Stress Disorder

NCT01605253
View directory record Official record
Conditions
Posttraumatic Stress Disorders
Interventions
Eszopiclone, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Sep 7, 2026, 1:34 AM EDT
Completed Early Phase 1 Interventional Results available

The Effect of Eszopiclone on the Arousal Threshold in Sleep Apnea Syndrome

NCT01102270
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Eszopiclone, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 7, 2026, 1:34 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

How do Sleeping Pills Affect Pain in the Brain?

NCT00414037
View directory record Official record
Conditions
Primary Insomnia
Interventions
Eszopiclone, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
20 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2015 · Synced Sep 7, 2026, 1:34 AM EDT
Completed Phase 2 Interventional

Endotype-Targeted Therapy to Rescue OSA Patients Struggling With CPAP Adherence (TOP-CPAP)

NCT05951023
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Eszopiclone 2 mg, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 7, 2026, 1:34 AM EDT
Completed Not applicable Interventional Results available

Sleep Loss and Mechanisms of Impaired Glucose Metabolism

NCT00555750
View directory record Official record
Conditions
Primary Insomnia
Interventions
eszopiclone, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
25 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Sep 7, 2026, 1:34 AM EDT
Completed Not applicable Interventional Results available

Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia

NCT00833547
View directory record Official record
Conditions
Schizophrenia
Interventions
eszopiclone, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Sep 7, 2026, 1:34 AM EDT
Completed Phase 3 Interventional

6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia

NCT00352144
View directory record Official record
Conditions
Primary Insomnia
Interventions
Eszopiclone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
21 Years to 64 Years
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
58
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 7, 2026, 1:34 AM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia

NCT00856973
View directory record Official record
Conditions
Insomnia, Attention Deficit Hyperactivity Disorder
Interventions
eszopiclone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
73
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2013 · Synced Sep 7, 2026, 1:34 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder

NCT00235508
View directory record Official record
Conditions
Insomnia, Generalized Anxiety Disorder
Interventions
Eszopiclone (Lunesta)
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
64
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 7, 2026, 1:34 AM EDT
Completed Phase 3 Interventional

Study of Eszopiclone Compared to Placebo in the Treatment of Insomnia Secondary to Perimenopause/Menopause

NCT00366093
View directory record Official record
Conditions
Insomnia
Interventions
Eszopiclone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
40 Years to 60 Years · Female only
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
51
States / cities
Mobile, Alabama • San Diego, California • Denver, Colorado + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 7, 2026, 1:34 AM EDT
Completed Phase 4 Interventional

Continuous Positive Airway Pressure (CPAP) Promotion And Prognosis - the Army Sleep Apnea Program (ASAP)

NCT00612157
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Eszopiclone, Placebo control
Drug
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years to 64 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 25, 2009 · Synced Sep 7, 2026, 1:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Daytime Eszopiclone Administration in Shift Workers

NCT00900159
View directory record Official record
Conditions
Shift-Work Sleep Disorder
Interventions
eszopiclone, matching placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
20 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Sep 7, 2026, 1:34 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Eszopiclone With Mild to Moderate Obstructive Sleep Apnea Syndrome (OSAS)

NCT00685269
View directory record Official record
Conditions
Obstructive Sleep Apnea Syndrome
Interventions
Eszopiclone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
2
States / cities
Atlanta, Georgia • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 7, 2026, 1:34 AM EDT
Completed Phase 4 Interventional Results available

Eszopiclone Treatment & Cortisol Responsivity

NCT00889200
View directory record Official record
Conditions
Insomnia
Interventions
eszopiclone
Drug
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Sep 7, 2026, 1:34 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban

NCT00511134
View directory record Official record
Conditions
Insomnia, Nicotine Dependence
Interventions
Eszopiclone, Bupropion
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 7, 2026, 1:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder

NCT00813735
View directory record Official record
Conditions
Insomnia
Interventions
Eszopiclone, Placebo, Escitalopram
Drug
Lead sponsor
Lehigh Center for Clinical Research
Other
Eligibility
65 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2012 · Synced Sep 7, 2026, 1:34 AM EDT
Completed Phase 2 Interventional Results available

Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea

NCT04639193
View directory record Official record
Conditions
OSA, Obstructive Sleep Apnea
Interventions
Acetazolamide, Eszopiclone, Placebo, Venlafaxine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Sep 7, 2026, 1:34 AM EDT
Completed Phase 4 Interventional Results available

Study of the Insomnia in Patients With Low Back Pain

NCT00365976
View directory record Official record
Conditions
Primary Insomnia
Interventions
Eszopiclone, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
21 Years to 64 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Sep 7, 2026, 1:34 AM EDT
Completed Not applicable Interventional

Eszopiclone for Improving Sleep in Multiple Sclerosis (MS)

NCT00594087
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis, Sleep Initiation and Maintenance Disorders, Fatigue
Interventions
eszopiclone, placebo
Drug · Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 4, 2009 · Synced Sep 7, 2026, 1:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Chronic Hypnotic Use 2

NCT02456532
View directory record Official record
Conditions
Chronic Insomnia
Interventions
placebo, Zolpidem CR, Eszopiclone
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Sep 7, 2026, 1:34 AM EDT